Compare GeneDx Holdings Corp (WGS) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? GeneDx Holdings Corp trades at $82.71 (market cap $2.44B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.31. The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| WGS | YMAG | |
|---|---|---|
Market Cap | $2.44B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $167.51 | $15.98 |
52-Week Low | $34.51 | $10.76 |
Enterprise Value | $2.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
YMAG trades at $11.29, down 2.59% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.07 to $0.40, highlighting its income-focused strategy. News coverage emphasizes distribution announcements and NAV stability concerns amid earnings volatility.
Outlook hinges on sustained option income generation, but risks include NAV decay from call spreads and market volatility. Analyst sentiment is mixed, with some viewing it as a tactical buy in rangebound markets. Key risks are earnings-driven NAV swings and competitive ETF structures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
